Monoamine Oxidase Inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Monoamine oxidase inhibitors (MAOIs) were the first antidepressants marketed in the beginning of the 1950s. They were found to be associated with serious drug "drug and drug" food adverse reactions manifested by symptoms of serious hyperadrenergic and hyperserotenergic excess. They have not been used as first-line antidepressants for many years, although they are still occasionally used to treat atypical and refractory depression. Selegiline, a selective monoamine oxidase B inhibitor, is used in the treatment of Parkinson's disease and is less likely to cause similar adverse reactions.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Toxicology
Subtitle of host publicationThird Edition
PublisherElsevier
Pages389-390
Number of pages2
ISBN (Electronic)9780123864543
ISBN (Print)9780123864550
DOIs
StatePublished - Jan 1 2014

Fingerprint

Monoamine Oxidase Inhibitors
Antidepressive Agents
Treatment-Resistant Depressive Disorder
Selegiline
Monoamine Oxidase
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Parkinson Disease
Food

Keywords

  • Isocarboxazid
  • Moclobemide
  • Monomamine oxidase inhibitor
  • Phenelzine
  • Selegiline
  • Serotonin syndrome
  • Tranylcypromine
  • Tryamine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wax, P. M. (2014). Monoamine Oxidase Inhibitors. In Encyclopedia of Toxicology: Third Edition (pp. 389-390). Elsevier. https://doi.org/10.1016/B978-0-12-386454-3.00753-3

Monoamine Oxidase Inhibitors. / Wax, P. M.

Encyclopedia of Toxicology: Third Edition. Elsevier, 2014. p. 389-390.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wax, PM 2014, Monoamine Oxidase Inhibitors. in Encyclopedia of Toxicology: Third Edition. Elsevier, pp. 389-390. https://doi.org/10.1016/B978-0-12-386454-3.00753-3
Wax PM. Monoamine Oxidase Inhibitors. In Encyclopedia of Toxicology: Third Edition. Elsevier. 2014. p. 389-390 https://doi.org/10.1016/B978-0-12-386454-3.00753-3
Wax, P. M. / Monoamine Oxidase Inhibitors. Encyclopedia of Toxicology: Third Edition. Elsevier, 2014. pp. 389-390
@inbook{18e75f8f14f3445599bb74ad263be3b9,
title = "Monoamine Oxidase Inhibitors",
abstract = "Monoamine oxidase inhibitors (MAOIs) were the first antidepressants marketed in the beginning of the 1950s. They were found to be associated with serious drug {"}drug and drug{"} food adverse reactions manifested by symptoms of serious hyperadrenergic and hyperserotenergic excess. They have not been used as first-line antidepressants for many years, although they are still occasionally used to treat atypical and refractory depression. Selegiline, a selective monoamine oxidase B inhibitor, is used in the treatment of Parkinson's disease and is less likely to cause similar adverse reactions.",
keywords = "Isocarboxazid, Moclobemide, Monomamine oxidase inhibitor, Phenelzine, Selegiline, Serotonin syndrome, Tranylcypromine, Tryamine",
author = "Wax, {P. M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-386454-3.00753-3",
language = "English (US)",
isbn = "9780123864550",
pages = "389--390",
booktitle = "Encyclopedia of Toxicology",
publisher = "Elsevier",

}

TY - CHAP

T1 - Monoamine Oxidase Inhibitors

AU - Wax, P. M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Monoamine oxidase inhibitors (MAOIs) were the first antidepressants marketed in the beginning of the 1950s. They were found to be associated with serious drug "drug and drug" food adverse reactions manifested by symptoms of serious hyperadrenergic and hyperserotenergic excess. They have not been used as first-line antidepressants for many years, although they are still occasionally used to treat atypical and refractory depression. Selegiline, a selective monoamine oxidase B inhibitor, is used in the treatment of Parkinson's disease and is less likely to cause similar adverse reactions.

AB - Monoamine oxidase inhibitors (MAOIs) were the first antidepressants marketed in the beginning of the 1950s. They were found to be associated with serious drug "drug and drug" food adverse reactions manifested by symptoms of serious hyperadrenergic and hyperserotenergic excess. They have not been used as first-line antidepressants for many years, although they are still occasionally used to treat atypical and refractory depression. Selegiline, a selective monoamine oxidase B inhibitor, is used in the treatment of Parkinson's disease and is less likely to cause similar adverse reactions.

KW - Isocarboxazid

KW - Moclobemide

KW - Monomamine oxidase inhibitor

KW - Phenelzine

KW - Selegiline

KW - Serotonin syndrome

KW - Tranylcypromine

KW - Tryamine

UR - http://www.scopus.com/inward/record.url?scp=85043260774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043260774&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-386454-3.00753-3

DO - 10.1016/B978-0-12-386454-3.00753-3

M3 - Chapter

AN - SCOPUS:85043260774

SN - 9780123864550

SP - 389

EP - 390

BT - Encyclopedia of Toxicology

PB - Elsevier

ER -